erenumab (aimovig) is the first of four new migraine drugs in the pipeline that target calcitonin gene-related peptide (cgrp), a molecule that's produced in nerve cells of the .-related side effects. its manufacturer, eli lilly, plans to submit a new drug application to the fda in the second half of 2018. .
derek valenzuela had a tough time coming up with words of gratitude for st. jude staffers. .